Herman de Kock

1.3k total citations
21 papers, 838 citations indexed

About

Herman de Kock is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Herman de Kock has authored 21 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hepatology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Herman de Kock's work include Hepatitis C virus research (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Cystic Fibrosis Research Advances (5 papers). Herman de Kock is often cited by papers focused on Hepatitis C virus research (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Cystic Fibrosis Research Advances (5 papers). Herman de Kock collaborates with scholars based in Sweden, Belgium and Netherlands. Herman de Kock's co-authors include Oliver Lenz, Pierre Raboisson, Kenneth Simmen, Gregory Fanning, Bertil Samuelsson, Åsa Rosenquist, Tse‐I Lin, Maxwell D. Cummings, Lotta Vrang and Michael Edlund and has published in prestigious journals such as Angewandte Chemie International Edition, Gastroenterology and Journal of Medicinal Chemistry.

In The Last Decade

Herman de Kock

20 papers receiving 822 citations

Peers

Herman de Kock
Rozenn Brillet France
Gulrez Fazal Canada
Pascale Dehertogh Belgium
Donghui Bao United States
John P. Maxwell United States
Shalini Bansal United States
Tse‐I Lin Sweden
Julie Blaising France
Meg Keilman United States
Rozenn Brillet France
Herman de Kock
Citations per year, relative to Herman de Kock Herman de Kock (= 1×) peers Rozenn Brillet

Countries citing papers authored by Herman de Kock

Since Specialization
Citations

This map shows the geographic impact of Herman de Kock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herman de Kock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herman de Kock more than expected).

Fields of papers citing papers by Herman de Kock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herman de Kock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herman de Kock. The network helps show where Herman de Kock may publish in the future.

Co-authorship network of co-authors of Herman de Kock

This figure shows the co-authorship network connecting the top 25 collaborators of Herman de Kock. A scholar is included among the top collaborators of Herman de Kock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herman de Kock. Herman de Kock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bell, Scott C., Peter J. Barry, K. De Boeck, et al.. (2019). CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. Journal of Cystic Fibrosis. 18(5). 700–707. 36 indexed citations
2.
Davies, Jane C., Silke van Koningsbruggen‐Rietschel, Pavel Dřevı́nek, et al.. (2019). GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1). Journal of Cystic Fibrosis. 18(5). 693–699. 22 indexed citations
3.
Minić, Predrag, Stijn Verhulst, Eva Van Braeckel, et al.. (2018). GLPG2222 in CF subjects homozygous for F508DEL : results from a phase II study (FLAMINGO). Ghent University Academic Bibliography (Ghent University). 1 indexed citations
4.
Verhulst, Stijn, Eva Van Braeckel, Patrick A. Flume, et al.. (2018). EPS3.05 GLPG2222 in subjects with cystic fibrosis homozygous for F508del: results from a phase II study (FLAMINGO). Journal of Cystic Fibrosis. 17. S42–S42. 2 indexed citations
5.
Boeck, K. De, Pavel Dřevı́nek, Barry J. Plant, et al.. (2018). WS01.4 GLPG2222 in subjects with cystic fibrosis and the F508del/Class III mutation on stable treatment with ivacaftor: results from a phase II study (ALBATROSS). Journal of Cystic Fibrosis. 17. S2–S2. 6 indexed citations
6.
Davies, Jane C., Silke van Koningsbruggen‐Rietschel, Gordon MacGregor, et al.. (2017). WS13.6 GLPG1837 in subjects with cystic fibrosis (CF) and the G551D mutation: results from a phase II study (SAPHIRA1). Journal of Cystic Fibrosis. 16. S24–S25. 4 indexed citations
7.
Rosenquist, Åsa, Bertil Samuelsson, Per-Ola Johansson, et al.. (2014). Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor. Journal of Medicinal Chemistry. 57(5). 1673–1693. 158 indexed citations
8.
Cummings, Maxwell D., Jimmy Lindberg, Tse‐I Lin, et al.. (2010). Innentitelbild: Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target (Angew. Chem. 9/2010). Angewandte Chemie. 122(9). 1552–1552. 1 indexed citations
9.
Gyseghem, Elke Van, Lieven Baert, P. Van Remoortere, et al.. (2010). Co-administration of darunavir and a new pharmacokinetic booster: Formulation strategies and evaluation in dogs. European Journal of Pharmaceutical Sciences. 41(2). 193–200. 6 indexed citations
10.
Cummings, Maxwell D., Jimmy Lindberg, Tse‐I Lin, et al.. (2010). Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target. Angewandte Chemie International Edition. 49(9). 1652–1655. 71 indexed citations
11.
Cummings, Maxwell D., Jimmy Lindberg, Tse‐I Lin, et al.. (2010). Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target. Angewandte Chemie. 122(9). 1696–1699. 4 indexed citations
12.
Lenz, Oliver, Thierry Verbinnen, Tse‐I Lin, et al.. (2010). In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435. Antimicrobial Agents and Chemotherapy. 54(5). 1878–1887. 178 indexed citations
13.
Lenz, Oliver, Jan Martin Berke, Herman de Kock, et al.. (2010). 759 COMBINATION OF TMC435 WITH TWO NOVEL NS5B INHIBITORS INCREASES ANTI HCV ACTIVITY AND RESULTS IN A HIGHER GENETIC BARRIER IN VITRO. Journal of Hepatology. 52. S295–S296. 2 indexed citations
14.
Reesink, H. W., Gregory Fanning, Christine J. Weegink, et al.. (2009). Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients. Gastroenterology. 138(3). 913–921. 123 indexed citations
15.
Lin, Tse‐I, Oliver Lenz, Gregory Fanning, et al.. (2009). In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. Antimicrobial Agents and Chemotherapy. 53(4). 1377–1385. 142 indexed citations
16.
Visser, M.R., Lieven Baert, Gerben van ‘t Klooster, et al.. (2009). Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240. European Journal of Pharmaceutics and Biopharmaceutics. 74(2). 233–238. 42 indexed citations
17.
Voets, Marieke, Jos Van Houdt, René Verloes, et al.. (2008). 855 ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER. Journal of Hepatology. 48. S321–S321. 3 indexed citations
18.
Raboisson, Pierre, Tse‐I Lin, Herman de Kock, et al.. (2008). Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(18). 5095–5100. 18 indexed citations
19.
Reesink, Hendrik W., René Verloes, Christine J. Weegink, et al.. (2008). 64 SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY. Journal of Hepatology. 48. S28–S29. 16 indexed citations
20.
Demling, L, Herman de Kock, & M. Claßen. (1972). The influence of pentagastrin and secretin on the PH in duodenum.. PubMed. 19(3). 186–9.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rozenn Brillet Breakdown of academic impact, for papers by Gulrez Fazal Breakdown of academic impact, for papers by Pascale Dehertogh Breakdown of academic impact, for papers by Donghui Bao Breakdown of academic impact, for papers by John P. Maxwell Breakdown of academic impact, for papers by Shalini Bansal Breakdown of academic impact, for papers by Tse‐I Lin Breakdown of academic impact, for papers by Julie Blaising Breakdown of academic impact, for papers by Meg Keilman
Rankless by CCL
2026